---
title: Negating Opioid and Pain Actively Through Intervention
nct_id: NCT03306147
overall_status: COMPLETED
phase: NA
sponsor: Loma Linda University
study_type: INTERVENTIONAL
primary_condition: Pain
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03306147.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03306147"
ct_last_update_post_date: 2019-02-12
last_seen_at: "2026-05-12T07:30:04.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Negating Opioid and Pain Actively Through Intervention

**NCT ID:** [NCT03306147](https://clinicaltrials.gov/study/NCT03306147)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 33
- **Lead Sponsor:** Loma Linda University
- **Collaborators:** Cardinal Health
- **Conditions:** Pain, Chronic Pain, Opioid Use
- **Start Date:** 2017-10-12
- **Completion Date:** 2018-05-17
- **CT.gov Last Update:** 2019-02-12

## Brief Summary

Chronic pain is one of the most prevalent and debilitating medical conditions and opioid analgesics are a commonly prescribed class of medications in the United States. Opioid efficacy has been proven in terms of managing acute and chronic pain; however, opioid overdose deaths, addictions, and diversions have all continued to increase over the years. The purpose of this study is to increase patient engagement in pain management and education, and to decrease opioid use by 10% over the study period. This study will also help present opportunities for future studies to obtain insight regarding the chronic use of opioids.

## Detailed Description

The institutional review board has approved this prospective single-center study at a large 900-bed academic university medical center. The electronic medical record system will identify 300 patients, who are at least 18 years of age, with a history of opioid use for 3 or more months, or who are currently prescribed and are using long-acting or extended release opioids. Procedures by student pharmacists, pharmacy residents, and pharmacists will include reviewing medical records and prescription drug monitoring programs for the use of opioids, evaluating baseline pain, quality of life, and satisfaction via questionnaires and assessment questions, and performing thorough medication consultations on current opioid regimens. Education of pain and promotion of adjunct and non-pharmacologic alternative therapies will be completed to engage patients in assessing their pain and seeing the effectiveness of their treatment. Patients will receive 3 follow-up interventions: 2 phone calls with a pharmacist or student pharmacist at weeks 2 and 6, and a follow-up visit with a pain or primary care physician. Opioid usage, pain, quality of life, and patient satisfaction will be assessed. The primary outcome measured will be a decrease in opioid usage in morphine milligram equivalents. Secondary outcomes include change in quality of life and patient satisfaction.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* at least 18 years of age
* history of opioid use for 3 or more months or
* currently prescribed and are using long-acting or extended release opioids

Exclusion Criteria:

* substance use
* oncology patients
* hematology patients
```

## Arms

- **Chronic pain or long-acting opioid use** (EXPERIMENTAL) — Education of pain and promotion of adjunct and non-pharmacologic alternative therapies will be completed to engage patients in assessing their pain and seeing the effectiveness of their treatment. Patients will receive 3 follow-up interventions: 2 phone calls with a pharmacist or student pharmacist at weeks 2 and 6, and a follow-up visit with a pain or primary care physician.

## Interventions

- **Pain education with follow up encounters** (BEHAVIORAL) — Patient pain review, counseling and education by pharmacists and physicians in follow up encounters

## Primary Outcomes

- **Decrease in opioid prescription strength** _(time frame: Change in prescription strength between date of subject enrollment and 90 days after subject enrollment date)_ — Opioid usage will be measured by changes in prescription strength of morphine milligram equivalents

## Secondary Outcomes

- **Reduction in pain as evidenced by decrease in opioid daily dose** _(time frame: Change in daily opioid use between date of subject enrollment and 90 days after subject enrollment date)_
- **Improvement in quality of life score as measured by the PEG pain screening tool by units on a scale** _(time frame: Change in quality of life score as measured by the PEG pain screening tool by units on a scale between date of subject enrollment and 90 days after subject enrollment date)_

## Locations (1)

- Loma Linda University, Loma Linda, California, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.loma linda university|loma linda|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03306147.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03306147*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*